Healius Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Paul Anderson

Amministratore delegato

AU$944.6k

Compenso totale

Percentuale dello stipendio del CEO	97.7%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Anderson rispetto agli utili di Healius?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	AU$945k	AU$923k	-AU$636m
Dec 31 2023	n/a	n/a	-AU$984m
Sep 30 2023	n/a	n/a	-AU$682m
Jun 30 2023	AU$235k	AU$194k	-AU$380m

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 609.87K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 1.08M ).

Compensazione vs guadagni: La retribuzione di Paul è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Paul Anderson

less than a year

Mandato

AU$944,623

Compensazione

Mr. Paul D. Anderson, B COMM, CA serves as Managing Director, Chief Executive Officer since 2024 at Healius Limited and had been Group Chief Financial Officer of Healius Limited since March 1, 2023 and als...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Anderson	MD, CEO & Director	less than a year	AU$944.62k	Nessun dato
Stephen Humphries	CFO& Company Secretary	1.7yrs	AU$718.57k	0.0024% A$ 23.0k
Jan Van Rooyen	Head & Group Executive of Healius Pathology	1.4yrs	AU$1.43m	Nessun dato
Paula Bayliss	Group Executive of People & Culture	less than a year	Nessun dato	Nessun dato
John McKechnie	Advisor	5.3yrs	AU$275.71k	0% A$ 0
Phil Lucas	Chief Executive of Lumus Imaging	1.8yrs	Nessun dato	Nessun dato
Ian Mcphan	Chief Operating Officer of Healius Pathology	no data	Nessun dato	Nessun dato
Sharon Ng	Head of Group FP&A	no data	Nessun dato	Nessun dato
Arjun Narang	Group Executive of Operations Transformation	1.5yrs	Nessun dato	Nessun dato
Jon Eide	Group Executive of Commercial & Customer	1.6yrs	Nessun dato	Nessun dato
Alejandro Rosales	Head of Digital Strategy & Delivery Office	no data	Nessun dato	Nessun dato
Mary Weaver	Company Secretary	1.7yrs	Nessun dato	Nessun dato

1.6yrs

Durata media

Gestione esperta: Il team dirigenziale di HLS non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Anderson	MD, CEO & Director	less than a year	AU$944.62k	Nessun dato
Gordon Davis	Non-Executive Director	9.3yrs	AU$180.18k	0.017% A$ 163.2k
Kathryn McKenzie	Interim Non-Executive Independent Chair	3.8yrs	AU$269.98k	0.014% A$ 133.7k
Michael Stanford	Independent Non-Executive Director	1.2yrs	AU$138.74k	0.0045% A$ 43.3k
Sally Evans	Independent Non-Executive Director	6.3yrs	AU$185.00k	0.013% A$ 128.7k
John Mattick	Non Executive & Independent Director	2.7yrs	AU$170.00k	0.0075% A$ 72.5k
Charlie Taylor	Independent Non-Executive Director	1.7yrs	AU$174.82k	0.018% A$ 177.4k

2.7yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di HLS non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.

Healius Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Healius Limited, Annual General Meeting, Nov 15, 2024

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

High number of new directors

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Recent updates

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Full year 2024 earnings released: AU$0.96 loss per share (vs AU$0.67 loss in FY 2023)

Healius Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings released

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

High number of new directors

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

Full year 2022 earnings released: EPS: AU$0.50 (vs AU$0.11 in FY 2021)

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Healius Reportedly Launches Day Surgery Sale Process

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold AU$713k worth of stock

Upcoming dividend of AU$0.068 per share

Full year 2021 earnings released: EPS AU$0.11 (vs AU$0.12 in FY 2020)

Healius Limited (ASX:HLS) acquired Axis Diagnostic Holdings Pty Limited.

Healius Reportedly to Sale Day Surgeries

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Healius Limited Appoints Kate McKenzie as A Non-Executive Director Effective from 25 February 2021

New 90-day high: AU$4.16

Healius Limited(ASX:HLS) dropped from S&P/ASX 100 Index

New 90-day high: AU$3.90

BGH Capital completed the acqusition of Primary Care Business of Healius Ltd from Healius Limited (ASX:HLS) for AUD485 million.

Independent Non Executive Director recently bought AU$53k worth of stock

New 90-day high: AU$3.77

Healius Limited Announces Retirement of Arlene Tansey as Non-Executive Director

New 90-day high: AU$3.46

Healius Limited to Report Fiscal Year 2021 Results on Aug 20, 2021